Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin (Prosemble nanoparticle reformulation)
- Development stage
- Preclinical
- Lead developer
- Prosemble
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
Prosemble's nanoparticle reformulation of doxorubicin is a preclinical-stage therapeutic designed to enhance the delivery and safety profile of the conventional anthracycline chemotherapy. By encapsulating doxorubicin within a nanoparticle carrier, the formulation aims to improve tumor-specific accumulation, potentially reducing the cardiotoxicity and other systemic side effects associated with free doxorubicin. The active agent, doxorubicin, exerts its antineoplastic effect by intercalating into DNA and inhibiting the enzyme topoisomerase II, which prevents DNA replication and induces apoptosis in rapidly dividing cancer cells. This reformulation is being evaluated for a broad range of indications, including breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, and acute lymphoblastic leukaemia.
- Other names
- Reformulated doxorubicinDoxorubicin nanoparticle formulationDoxorubicin (reformulated)
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on doxorubicin (Prosemble nanoparticle reformulation).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin (Prosemble nanoparticle reformulation).